Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
APD209 (formerly ACA1209)
print preview
bookmark
share with colleague
General Information
Company
Acacia Pharma Ltd.
Description
Oral fixed-dose combination of a progestin and a selective ADRB2 agonist
Molecular Target
Adrenergic receptor beta 2 (ADRB2)
Mechanism of Action
Adrenergic receptor beta 2 (ADRB2) agonist
Latest Stage of Development
Phase II
Indication
Cachexia
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy